日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants.

针对SARS-CoV-2变异株具有广泛中和作用的纳米颗粒疫苗的免疫原性和保护性

Logue James, Johnson Robert M, Patel Nita, Zhou Bin, Maciejewski Sonia, Foreman Bryant, Zhou Haixia, Portnoff Alyse D, Tian Jing-Hui, Rehman Asma, McGrath Marisa E, Haupt Robert E, Weston Stuart M, Baracco Lauren, Hammond Holly, Guebre-Xabier Mimi, Dillen Carly, Madhangi M, Greene Ann M, Massare Michael J, Glenn Greg M, Smith Gale, Frieman Matthew B

Pyronaridine tetraphosphate is an efficacious antiviral and anti-inflammatory active against multiple highly pathogenic coronaviruses.

吡咯萘啶四磷酸是一种有效的抗病毒和抗炎药,对多种高致病性冠状病毒具有活性

Ardanuy Jeremy, Johnson Robert, Dillen Carly, Taylor Louis, Hammond Holly, Weston Stuart, Frieman Matthew

Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients

结合病历分析的靶点无关药物预测揭示了他汀类药物与新冠肺炎患者生存率提高之间的差异性关联

Sperry, Megan M; Oskotsky, Tomiko T; Marić, Ivana; Kaushal, Shruti; Takeda, Takako; Horvath, Viktor; Powers, Rani K; Rodas, Melissa; Furlong, Brooke; Soong, Mercy; Prabhala, Pranav; Goyal, Girija; Carlson, Kenneth E; Wong, Ronald J; Kosti, Idit; Le, Brian L; Logue, James; Hammond, Holly; Frieman, Matthew; Stevenson, David K; Ingber, Donald E; Sirota, Marina; Novak, Richard

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

SARS-CoV-2 重组刺突蛋白疫苗 (NVX-CoV2373) 同源加强剂接种后的安全性和免疫原性:一项随机、安慰剂对照 II 期试验的二次分析

Mallory, Raburn M; Formica, Neil; Pfeiffer, Susan; Wilkinson, Bethanie; Marcheschi, Alex; Albert, Gary; McFall, Heather; Robinson, Michelle; Plested, Joyce S; Zhu, Mingzhu; Cloney-Clark, Shane; Zhou, Bin; Chau, Gordon; Robertson, Andreana; Maciejewski, Sonia; Hammond, Holly L; Baracco, Lauren; Logue, James; Frieman, Matthew B; Smith, Gale; Patel, Nita; Glenn, Gregory M

Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2.

对两种非竞争性中和单克隆抗体混合物 amubarvimab 和 romlusevimab 进行针对 SARS-CoV-2 的临床前表征

Ji Yun, Zhang Qi, Cheng Lin, Ge Jiwan, Wang Ruoke, Fang Mengqi, Mucker Eric M, Chen Peng, Ma Ji, Zhang Rui, Li Chunming, Hammond Holly, Baracco Lauren, Holbrook Michael, Frieman Matthew, Zhang Zheng, Wang Xinquan, Hooper Jay W, Zhang Linqi, Zhu Qing

Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infection

嘧啶生物合成抑制剂与核苷类似物协同作用,可阻断SARS-CoV-2感染。

Schultz, David C; Johnson, Robert M; Ayyanathan, Kasirajan; Miller, Jesse; Whig, Kanupriya; Kamalia, Brinda; Dittmar, Mark; Weston, Stuart; Hammond, Holly L; Dillen, Carly; Castellana, Lauren; Lee, Jae Seung; Li, Minghua; Lee, Emily; Constant, Samuel; Ferrer, Marc; Thaiss, Christoph A; Frieman, Matthew B; Cherry, Sara

p47 licenses activation of the immune deficiency pathway in the tick Ixodes scapularis

p47 激活了肩胛硬蜱(Ixodes scapularis)的免疫缺陷通路。

McClure Carroll, Erin E; Wang, Xiaowei; Shaw, Dana K; O'Neal, Anya J; Oliva Chávez, Adela S; Brown, Lindsey J; Boradia, Vishant Mahendra; Hammond, Holly L; Pedra, Joao H F